Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HYPOFIBRINOLYTIC AND ATHEROGENIC RISK-FACTORS FOR STROKE
Autore:
GLUECK CJ; RORICK MH; SCHMERLER M; ANTHONY J; FEIBEL J; BASHIR M; GLUECK HI; STROOP D; WANG Y; TRACY TM;
Indirizzi:
UNIV CINCINNATI,JEWISH HOSP CINCINNATI,CTR CHOLESTEROL,3200 BURNET AVE CINCINNATI OH 45229
Titolo Testata:
The Journal of laboratory and clinical medicine
fascicolo: 3, volume: 125, anno: 1995,
pagine: 319 - 325
SICI:
0022-2143(1995)125:3<319:HAARFS>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
DENSITY-LIPOPROTEIN CHOLESTEROL; ISCHEMIC CEREBROVASCULAR-DISEASE; PLASMINOGEN-ACTIVATOR INHIBITOR; CAROTID ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; LP(A) LIPOPROTEIN; PLASMA; BLOOD; FIBRINOLYSIS; MEN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
52
Recensione:
Indirizzi per estratti:
Citazione:
C.J. Glueck et al., "HYPOFIBRINOLYTIC AND ATHEROGENIC RISK-FACTORS FOR STROKE", The Journal of laboratory and clinical medicine, 125(3), 1995, pp. 319-325

Abstract

In 87 patients (studied on average 1 year after their strokes) and 26of their first-degree relatives, our specific aim was to assess the prevalence of the following stroke risk factors: hypofibrinolysis, familial hypofibrinolysis, high lipoprotein (a) level, and dyslipidemia. At least 2 months after their strokes (primarily ischemic), 87 patientshad measures of lipids and lipoprotein (a); 69 and 67 patients had measures of basal and stimulated fibrinolytic activity, respectively, four new findings were as follows. (1) Hypofibrinolysis was common, withbottom decile-stimulated tissue plasminogen activator activity (the major stimulator of fibrinolysis) in 21% of stroke probands and in 30% of their first-degree relatives, versus 7% of 29 normolipidemic control subjects (p = 0.09 and 0.026, respectively). (2) The hypofibrinolysis was mediated by top-decile levels of basal plasminogen activator inhibitor activity (the major inhibitor of fibrinolysis), which were observed in 20% of stroke probands and in 21% of their first-degree relatives, versus 8% of 175 normolipidemic control subjects (p = 0.007 and 0.04, respectively), Mean (SD) basal plasminogen activator inhibitor activity and antigen level were higher in stroke probands (18 +/- 18 U/ml and 35 +/- 31 ng/ml, respectively) than in the 175 normolipemic control subjects (14 +/- 10 [p = 0.02], 28 +/- 34 [p = 0.016]). (3) Levelsof basal tissue plasminogen activator antigen, a probable marker for atherosclerosis, were much higher in stroke probands than in the 175 normolipemic control subjects (15 +/- 7.3 ng/ml vs 7 +/- 3.8, p = 0.0001). (4) High lipoprotein (a) level (>35 mg/dl) was very common, seen in 48% of stroke probands versus 20% of 398 hyperlipidemic control subjects (p = 0.0001). Dyslipidemia was also common in stroke probands, with low levels of high-density lipoprotein cholesterol (<35 mg/dl) in 16%, high levels of low-density lipoprotein cholesterol (>160 mg/dl) in22%, and high triglyceride level (>250 mg/dl) in 20%. In patients with ischemic cerebral vascular disease atherogenic (dyslipidemia, high lipoprotein [a] level) and hypofibrinolytic (high plasminogen activatorinhibitor level) stroke risk factors are common and often familiar, should be routinely measured, and, where possible, treated to ameliorate and potentially to reverse ischemic stroke.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 07:14:46